Saturday 24 August 2019 ,
Saturday 24 August 2019 ,
Latest News
  • Repatriation unfeasible ‘without favourable environment’
  • Two more die of dengue, 1,445 patients hospitalised
  • AL to field best guns for city polls
  • 9-year dredging project taken to tackle floods
  • Enemies of Hindus are enemies of the nation: Quader
5 August, 2019 00:00 00 AM

FDA approves Accrufer (ferric maltol) for the treatment of Iron deficiency in adults

drugs.com
FDA approves Accrufer (ferric maltol) for the treatment of Iron deficiency in adults

Shield Therapeutics plc, a commercial stage, pharmaceutical company with a focus on addressing iron deficiency, announces that the U.S. Food and Drug Administration (FDA) has approved its lead product Accrufer® (Feraccru® in the European Union and Switzerland) for the treatment of iron deficiency in adults.

With this broad label approval Accrufer (as the product will be marketed in the USA) has taken a big step towards exploiting the very large commercial opportunity in the USA, the world’s largest and most attractively reimbursed pharmaceutical market.

Market research suggests that the prescription market for iron replacement therapy in the USA is worth over $1.0bn annually. There are between 8 million and 9 million patients in the USA who suffer from iron deficiency anaemia and management estimate potentially two to three times this number require treatment for iron deficiency.

Accrufer’s confirmed efficacy, together with its good tolerability and mode of absorption - by which the body absorbs only as much iron from Accrufer as it needs - means that the product could be the ideal choice for iron deficient patients who cannot tolerate salt-based oral iron alternatives.

These features, combined with the noninferiority results from the AEGIS-H2H study announced in March 2019, mean that treatment with Accrufer might remove the need for patients to progress to intravenous iron therapy, leading to a change in the current paradigm for the treatment of iron deficiency anaemia.

Together with its advisors, Shield is in discussions with a number of potential commercial partners for the US opportunity for Accrufer and looks forward to providing updates on these discussions in due course.

Feraccru is already approved in both the European Union and Switzerland for the treatment of iron deficiency in adults and commercialisation activities in these territories are progressing well via Shield’s licensing partners.

Carl Sterritt, CEO of Shield Therapeutics: “We are delighted that the FDA has approved the new drug application for our lead asset. This is a further major milestone for the Company which we have worked tirelessly to achieve, and I am very proud to lead the team within Shield that has made this happen.

With this broad approval and IP protection out to 2035, Feraccru®/ Accrufer® has a real and very attractive long-term market opportunity to exploit in the USA.

We have been pleased with the levels of interest and engagement shown by 3rd parties in commercialising Accrufer® in the USA and we look forward to finalising these discussions and appointing a commercial partner In the world’s most attractive pharmaceutical market,so that more patients with iron deficiency can benefit from treatment with Accrufer® at the earliest opportunity.”

Jackie Mitchell, VP Regulatory Affairs of Shield Therapeutics: “The broad label that the FDA has granted provides a very strong signal as to the tolerability and efficacy profile of Feraccru®/ Accrufer® and provides a novel and convenient treatment alternative to the millions of US patients who routinely suffer with iron deficiency.

We believe that this broad approval, together with the recent clinical trial data on Feraccru® that showed it to be non-inferior in treatment effect to Ferinject®/ Injectafer®, the leading IV iron therapy, can lead to a change in the current paradigm for the treatment iron deficiency anaemia.”

 

Comments

Most Viewed
Digital Edition
More story
Editor Speaks

Editor Speaks

Nutrition starts in the embryonic life as the trophoblast cells invade the deciduas digesting and imbibing it. Progesterone secreted during last half…
Overview of nutrition

Overview of nutrition

Nutrition id the process of providing or obtaining the food necessary for health and growth particularly in humans. It is the nourishment of energy and…
Nutritional disorders

Nutritional disorders

John C.M. Brust Nutritional deficiency can adversely affect the nervous system, both centrally and peripherally, leading to problems in thinking and other…
Nutritional status in Bangladesh

Nutritional status in Bangladesh

Rates of malnutrition in Bangladesh are among the highest in the world. More than 54% of preschool-age children, equivalent to more than 9.5 million children,…
Global nutrition targets 2025

Global nutrition targets 2025

Recognizing that accelerated global action is needed to address the pervasive and corrosive problem of the double burden of malnutrition, in 2012 the…
10 facts on nutrition

10 facts on nutrition

Nutrition is a critical part of health and development. Better nutrition is related to improved infant, child and maternal health, stronger immune systems,…
What exactly is a disease?

What exactly is a disease?

DUANE MELLOR There is an ongoing lively debate among healthcare professionals about whether or not obesity is a disease. Differences between those who…
OB/GYNs explain when you should (and shouldn’t) worry about period blood clots

OB/GYNs explain when you should (and shouldn’t) worry about period blood clots

KAITLYN PIRIE Even though blood clots sound scary, they’re usually a good thing. When you experience an injury—say, you accidentally cut yourself—your…
Deadly new fungal superbug is worrying doctors — here's what you need to know

Deadly new fungal superbug is worrying doctors — here's what you need to know

ABBY HAGLAGE Months after health officials in New York, New Jersey and Illinois raised concerns about a new deadly fungal superbug, a study has suggested…
Should you take daily aspirin for your heart?

Should you take daily aspirin for your heart?

LINDSEY KONKEL  Nearly 30 million Americans who are 40 or older—who don’t have cardiovascular disease—take aspirin every day anyway,…
SHARE project of icddr,b launch documentary films on prevention of NCDs

SHARE project of icddr,b launch documentary films on prevention of NCDs

Recently, Strengthening Health, Applying Research Evidence (SHARE) project of icddr,b in collaboration with University College London (UCL), United Kingdom…
Lyme disease: Older white women 'at highest risk'

Lyme disease: Older white women 'at highest risk'

Older women are at most risk of contracting Lyme disease, a study suggests - and parts of southern and south-west England are "hotspots". There…
FDA approves Pretomanid for highly drug-resistant forms of tuberculosis

FDA approves Pretomanid for highly drug-resistant forms of tuberculosis

Pretomanid, a novel compound developed by the non-profit organization TB Alliance, was approved by the U.S. Food & Drug Administration (FDA) recently…

Copyright © All right reserved.

Editor : M. Shamsur Rahman

Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Editor : M. Shamsur Rahman
Published by the Editor on behalf of Independent Publications Limited at Media Printers, 446/H, Tejgaon I/A, Dhaka-1215.
Editorial, News & Commercial Offices : Beximco Media Complex, 149-150 Tejgaon I/A, Dhaka-1208, Bangladesh. GPO Box No. 934, Dhaka-1000.

Disclaimer & Privacy Policy
....................................................
About Us
....................................................
Contact Us
....................................................
Advertisement
....................................................
Subscription

Powered by : Frog Hosting